首页> 外文期刊>Current cancer drug targets >Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
【24h】

Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer

机译:前列腺癌中的雄激素受体辅因子:去势抵抗性前列腺癌的潜在治疗靶点

获取原文
获取原文并翻译 | 示例
           

摘要

Androgens, acting through the androgen receptor (AR), are responsible for many male reproductive and non-reproductive functions. Moreover, aberrant androgen/AR signaling plays a critical role in androgen-dependent prostate cancer (PCa) as well as castration-resistant prostate cancer (CRPC). The formation of a productive AR transcriptional complex requires AR cofactors that interact functionally and structurally with the AR. Since the discovery of the first such cofactor in 1995, an ever increasing number of proteins have been identified as AR coactivators or compressors. The expression and function of several AR cofactors have been investigated in PCa, and a clear link between AR cofactors and the development and progression of PCa has been identified. Recently, AR splice variants in CRPC were reported, which display significant constitutive activity in the absence of ligand. Then, this discovery revolutionized the concept of AR cofactors in CRPC. The current review aims to provide an overview of AR cofactor proteins in the context of PCa. m addition, we discuss the potential of AR cofactors as novel therapeutic targets for PCa, particularly for CRPC.
机译:雄激素通过雄激素受体(AR)起作用,负责许多雄性生殖和非生殖功能。此外,异常的雄激素/ AR信号传导在雄激素依赖性前列腺癌(PCa)以及去势抵抗性前列腺癌(CRPC)中起关键作用。生产性AR转录复合物的形成需要与AR在功能上和结构上相互作用的AR辅因子。自1995年发现第一个此类辅助因子以来,越来越多的蛋白质被鉴定为AR辅助激活剂或压缩机。已经在PCa中研究了几种AR辅助因子的表达和功能,并且已经确定了AR辅助因子与PCa的发育和进程之间的明确联系。最近,报道了CRPC中的AR剪接变体,其在不存在配体的情况下显示出显着的组成活性。然后,这一发现彻底改变了CRPC中AR辅助因子的概念。本综述旨在提供PCa背景下AR辅助因子蛋白的概述。此外,我们讨论了AR辅助因子作为PCa尤其是CRPC的新型治疗靶标的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号